Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Kirsten Harbom"'
Publikováno v:
Biochemical and Biophysical Research Communications. 434:70-74
The high mobility group A1 gene (HMGA1) has been previously implicated in breast carcinogenesis, and is considered an attractive target for therapeutic intervention because its expression is virtually absent in normal adult tissue. Other studies have
Autor:
Emmanouil P. Pappou, William Matsui, David Feller-Kopman, Lonny Yarmus, Yi Cai, Carine Robert, Il Minn, Alana L. Welm, James C. Harris, Robert Beaty, Huili Li, Feyruz V. Rassool, Jean Pierre J. Issa, James Shin, Vered Stearns, Yoon Young Jang, Yi Chun Lin, Nita Ahuja, Cynthia A. Zahnow, Saul J. Sharkis, Kirsten Harbom, Hsing-Chen Tsai, Leander Van Neste, Ray Whay Chiu Yen, Malcolm V. Brock, Stephen B. Baylin
Publikováno v:
Cancer Cell. 21:430-446
SummaryReversal of promoter DNA hypermethylation and associated gene silencing is an attractive cancer therapy approach. The DNA methylation inhibitors decitabine and azacitidine are efficacious for hematological neoplasms at lower, less toxic, doses
Autor:
James Shin, Kristen Pelosky, Cynthia A. Zahnow, Cory Brayton, Kirsten Harbom, Beverly Lee, Craig M. Hooker, Alicia Hulbert, Malcolm V. Brock, Stephen B. Baylin, Stephen C. Yang, James E. Harris
Publikováno v:
Journal of Surgical Research. 171:e75-e79
Background The flank is commonly used for primary xenografts in mice, but it is rare for these tumors to metastasize. Tail vein injection creates a pattern of metastases, but is artificial. We hypothesized that the liver is a convenient alternative x
Autor:
Princy Parsana, Suzanne L. Topalian, Helai P. Mohammad, Cynthia A. Zahnow, Julie R. Brahmer, Wei Wang, Xiaoyu Pan, Alexander Koch, Kirsten Harbom, John Wrangle, Charles M. Rudin, Kristen Rodgers, Peter A. Jones, Malcolm V. Brock, Janis M. Taube, Stephen B. Baylin, Drew M. Pardoll, Hariharan Easwaran, Frank P. Vendetti
Publikováno v:
Cancer Research. 73:4619-4619
Epigenetic alterations driving carcinogenesis and cancer progression can be specifically targeted by the demethylating agent azacitidine (Aza) and the histone deacetylase inhibitor entinostat. While this treatment combination has been effective in a
Autor:
Helai P. Mohammad, James G. Herman, Kirsten Harbom, James Shin, Rosalyn A. Juergens, Cynthia A. Zahnow, Malcolm V. Brock, Stephen B. Baylin, Charles M. Rudin, Kristen Rodgers, John Wrangle, Abde M. Abukhdeir
Publikováno v:
Journal of Clinical Oncology. 30:e18147-e18147
e18147 Background: A completed clinical trial has demonstrated activity of a combination of epigenetic therapies: entinostat, a histone deacetylase inhibitor, and azacytidine (AZA), a hypomethylating agent. A plasma-based biomarker assaying methylati
Autor:
Alana L. Welm, Yi Cai, Feyruz V. Rassool, Emmanouil P. Pappou, James C. Harris, Il Minn, Malcolm V. Brock, Vered Stearns, Stephen B. Baylin, Carine Robert, Jean Pierre J. Issa, Robert Beaty, Yoon-Young Jang, Yi Chun Lin, Hsing-Chen Tsai, Leander Van Neste, Ray-Whay Chiu Yen, Huili Li, William Matsui, David Feller-Kopman, Kirsten Harbom, Cynthia A. Zahnow, Nita Ahuja, James Shin, Saul J. Sharkis
Publikováno v:
Cancer Research. 72:995-995
Reversal of gene promoter DNA hypermethylation and associated abnormal gene silencing is an attractive approach to cancer therapy. The DNA methylation inhibitors, decitabine (5-aza-2′-deoxycytidine) and azacitidine (5-azacytidine) are proving effic
Autor:
Kirsten Harbom, Robert Beaty, V Lynn Flowers, Brent Gordon, James Shin, Cory Brayton, Wei Wang, Cynthia A. Zahnow, Briana Vecchio-Pagan, Huili Li, Stephen B. Baylin, Francescopaolo Di Cello
Publikováno v:
Molecular Cancer
Background Recent epidemiological studies demonstrate that both active and involuntary exposure to tobacco smoke increase the risk of breast cancer. Little is known, however, about the molecular mechanisms by which continuous, long term exposure to t